Compare FFIC & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FFIC | IVVD |
|---|---|---|
| Founded | 1929 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 510.6M | 437.1M |
| IPO Year | 1996 | 2021 |
| Metric | FFIC | IVVD |
|---|---|---|
| Price | $15.96 | $1.12 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $16.80 | $8.75 |
| AVG Volume (30 Days) | 193.4K | ★ 2.4M |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | ★ 5.50% | N/A |
| EPS Growth | ★ 151.43 | 79.02 |
| EPS | ★ 0.17 | N/A |
| Revenue | $7,455,000.00 | ★ $53,426,000.00 |
| Revenue This Year | $14.57 | $61.57 |
| Revenue Next Year | $6.64 | $41.42 |
| P/E Ratio | $93.76 | ★ N/A |
| Revenue Growth | 7.31 | ★ 110.47 |
| 52 Week Low | $11.13 | $0.49 |
| 52 Week High | $17.79 | $3.07 |
| Indicator | FFIC | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 52.99 | 35.84 |
| Support Level | $15.56 | $1.11 |
| Resistance Level | $16.58 | $1.14 |
| Average True Range (ATR) | 0.32 | 0.11 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 63.36 | 17.12 |
Flushing Financial Corp is a bank holding company. Through its subsidiary, the company is engaged in attracting retail deposits from the general public and investing those deposits together with funds generated from ongoing operations and borrowings, mainly in originations and purchases of multi-family residential properties loans, commercial business loans, commercial real estate mortgage loans and, to a lesser extent, one-to-four family loans (focusing on mixed-use properties, which are properties that contain both residential dwelling units and commercial units). It also operates an internet branch, under the brands of iGObanking.com and BankPurely. The company operates as a single unit, a community bank.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.